Inflammation-Driven Cancer: Mechanisms to Therapymembs.org/membs/uploads/news_images/cancer_document.pdf · immunity and inflammation are key determinants of tumor development and

Global Health Travel Award Application Deadline: September 6, 2016 Scholarship Application & Discounted Abstract Deadline: October 6, 2016Abstract Deadline: November 3, 2016Discounted Registration Deadline: December 7, 2016

Scientific Organizers: Fiona M. Powrie, University of Oxford, UK Michael Karin, University of California, San Diego, USA Alberto Mantovani, Humanitas University, Italy Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Joint with the meeting on Microbiome in Health and Disease

Carcinogenesis is the result of a complex interplay of cell intrinsic and extrinsic processes that promote genomic instability, sustained proliferation, resistance to apoptosis, reprogramming and reorganization of the stromal environment. An immune cell infiltrate is a characteristic feature of many tumors, and it is increasingly appreciated that immunity and inflammation are key determinants of tumor development and progression. This meeting will consider the molecular and environmental factors that shape the extensive cross-talk between immune, stromal and cancer cells in the tumor microenvironment. Positioned at the interface of cancer cell signaling, stem cells, inflammatory pathways and microbial drivers, this meeting should provide new insights into the factors that control the balance between tumor-promoting and tumor-suppressive immunity and inflammation and how this can be applied in the prevention and treatment of cancer. The meeting will attract a multi-disciplinary group of cancer cell biologists, immunologists and inflammation biologists and will be of interest to basic and clinical scientists alike.

Session Topics: • Inflammation-Driven Cancer• Microbiome and Cancer (Joint)• Inflammation and Cancer Stem Cells• Tumor-Elicited Inflammation• Inflammation and Immunity Crosstalk I & II• Stromal Cells and the Tumor Microenvironment • Prevention and Therapy

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230

a 501(c)(3) nonprofit educational organization

February 5–9, 2017 | Keystone Conference Center | Keystone, Colorado | USA

Inflammation-Driven Cancer: Mechanismsto Therapy

Note: Scholarships are available for graduate students and postdoctoral fellows and are awarded based on the abstract submitted. Global Health Travel Awards are for investigators from low and middle income countries.Upper image courtesy of National Center for Advancing Translational Sciences (NCATS), NIH Image Gallery

Meeting Hashtag: #KSinflamcancer www.keystonesymposia.org/17J7

SUNDAY, FEBRUARY 5Arrival and Registration

MONDAY, FEBRUARY 6Welcome and Keynote Address (J7)*Fiona M. Powrie, University of Oxford, UKLisa M. Coussens, Oregon Health & Science University, USAManipulating the Tumor Microenvironment in Cancer Therapy

Welcome and Keynote Address (J8)*William Michael Dunne, bioMérieux, Inc., USASarkis K. Mazmanian, California Institute of Technology, USAThe Gut-Microbiome-Brain Connection in Neurological Diseases

Inflammation Driven Cancer (J7)*Michael Karin, University of California, San Diego, USAFiona M. Powrie, University of Oxford, UKInflammation Driven Cancer: Host and Microbial PathwaysMathias Florian Heikenwälder, German Cancer Research Center,DKFZ, GermanyOn the Role of Immune Cells in NASH and NASH to HCC TransitionArthur Kaser, University of Cambridge, UKER Stress and Colorectal CancerJeonghyun Ahn, University of Miami, USAShort Talk: The Role of STING in Suppressing Inflammation-DrivenIntestinal TumorigenesisMatthias Ernst, Olivia Newton-John Cancer Research Institute,AustraliaShort Talk: Excessive HCK Kinase Activity in the Tumor StromaPolarizes Macrophages and Promotes Solid Malignancies

Monitoring Microbiome to Predict Disease Risk (J8)*William Michael Dunne, bioMérieux, Inc., USARamnik Xavier, Massachusetts General Hospital and Broad Institute,USAIBD, Crohn’s MicrobiomeDan R. Littman, HHMI, New York University School of Medicine, USARegulation of T Cell Responses by MicrobiotaCurtis C. Harris, NCI, National Institutes of Health, USAMicrobiome-TP53 Gene Interaction in Human Lung Cancer

NIH Institutes’ Interests in Microbiome Research (J8)*Robert W. Karp, National Institutes of Health, USARyan Ranallo, NIAID, National Institutes of Health, USAPhil J. Daschner, NCI, National Institutes of Health, USAElisabet Caler, NHLBI, National Institutes of Health, USARicardo Cibotti, NIAMS, National Institutes of Health, USAFrancesca Macchiarini, NIA, National Institutes of Health, USA

Workshop 1: Inflammation-Driven Cancer (J7)*Mathias Florian Heikenwälder, German Cancer Research Center,DKFZ, Germany*Hua E. Yu, Beckman Research Institute, City of Hope, USARyan Kolb, University of Iowa, USAIL-1beta promotes obesity-driven breast cancer progression throughthe upregulation of ANGPTL4 in adipocytesSarah McCuaig, University of Oxford, UKCytokine-Oncogene Synergies in Colorectal CancerSeyed Javad Moghaddam, University of Texas MD Anderson CancerCenter, USAMuc5ac Plays an Essential Role in Promotion of K-ras Mutant LungCancer by Inflammation Karen Pickering, Beatson Institute, UKGuanine Nucleotide Exchange Factor Vav1 Promotes Survival inColorectal Cancer through T-Cell ActivationNa-Young Song, NCI, National Institutes of Health, USADetermining the Signaling Pathway ofEpithelial-IKKalpha-Deletion-Mediated Symbiotic Bacterial and FungalInfection in Carcinogenesis Chunfeng Qu, Cancer Institute/Hospital, Chinese Academy ofMedical Sciences, ChinaLiver Inflammatory Macrophages in Response to Hepatitis B Virus(HBV) Proteins Promote Hepatocellular Carcinoma by EnhancingAngiogenesis through IL23/IL23R Interaction Martina Seiffert, German Cancer Research Center, GermanyTumor Exosome-Derived Y RNA Activates TLR7/8 Signaling inMonocytes and Contributes to Cancer Inflammation and ImmuneEscape

Workshop 1: Microbiome in Health and Disease (J8)*Ami S. Bhatt, Stanford University, USAMichael C. Abt, Sloan Kettering Institute, USAHost Immune Response Supports Fecal MicrobiotaTransplant-Mediated Clearance of Clostridium Difficile InfectionDingding An, Harvard Medical School, USAMicrobial Sphingolipids Modulate Host Epithelium Homeostasis andDiseaseNaama Geva-Zatorsky, Harvard Medical School, USAGut Microbiota-Host Interactions and their Immune ModulationsYun-Gi Kim, Keio University, JapanNeonatal Acquisition of Clostridia Species Controls ColonizationResistance Against Bacterial PathogensMonica Viladomiu, Weill Cornell Medicine, USAFunctional Characterization of IgA-Targeted E. coli in Crohn'sDisease-Associated Spondyloarthritis Links Mucosal Immunity withSystemic Inflammation

* Session Chair † Invited but not yet accepted Program current as of January 15, 2017. Program subject to change. Meal formats are based on meeting venue.For the most up-to-date details, visit www.keystonesymposia.org/17J7 and www.keystonesymposia.org/17J8.

KEYSTONE SYMPOSIAon Molecular and Cellular Biology

Inflammation-Driven Cancer: Mechanisms to Therapy (J7)Scientific Organizers: Fiona M. Powrie, Michael Karin and Alberto Mantovani

Sponsored by Incyte Corporation, Merck & Co., Inc. and Roche. Part of the Keystone Symposia Global Health Series, supported by the Bill &Melinda Gates Foundation.

Microbiome in Health and Disease (J8)Scientific Organizers: Julie A. Segre, Ramnik Xavier and William Michael Dunne

February 5-9, 2017 • Keystone Resort • Keystone, Colorado, USASponsored by Intercept Pharmaceuticals, Inc., Merck & Co., Inc. and Novartis Institutes for BioMedical Research. Part of the Keystone Symposia

Global Health Series, supported by the Bill & Melinda Gates Foundation. Global Health Travel Award Deadline: September 6, 2016 / Abstract & Scholarship Deadline: October 6, 2016 / Abstract Deadline: November 3, 2016 / Discounted

Registration Deadline: December 7, 2016

Xochitl Morgan, University of Otago, New ZealandGut Microbiota Acquisition in New Zealand Children in Relation toEarly Life Exposures Including Probiotics: A Longitudinal AnalysisAna Weil, Massachusetts General Hospital, USAThe Human Gut Microbiota and Susceptibility to Vibrio cholerae O1Infection

Microbiome and Cancer (Joint) *Arthur Kaser, University of Cambridge, UKLaurence Zitvogel, Institut Gustave Roussy, FranceMicrobe Driven Anti-Tumor ImmunityGiorgio Trinchieri, NCI, National Institutes of Health, USARole of the Microbiota in Inflammation, Carcinogenesis and CancerTherapyCurtis Huttenhower, Harvard School of Public Health, USAFunctional Analysis of Strains in the Human Gut MetatranscriptomeCynthia L. Sears, Johns Hopkins University School of Medicine, USAThe Carcinogenic Potential of Bacterial Biofilms

Poster Session 1

TUESDAY, FEBRUARY 7Inflammation and Cancer Stem Cells (J7)*Owen J. Sansom, Beatson Institute of Cancer Research, UKFlorian R. Greten, Institute for Tumor Biology and ExperimentalTherapy, GermanyStem Cells and Intestinal TumorogenesisSimon J. Leedham, University of Oxford, UKMorphogen Signaling in Intestinal Inflammation and CarcinogenesisFiona M. Watt, King's College London School of Medicine, UKContribution of Different Epidermal Cell Populations toInflammation-Associated CancersJudith A. Varner, University of California, San Diego, USATalk Title to be AnnouncedMin-Kyung Choo, Massachusetts General Hospital/Harvard MedicalSchool, USAShort Talk: p38 MAPK Functions as a Tumor Suppressor in SkinEpithelial Cells, but as a Tumor Promoter in Myeloid CellsJelena Todoric, University of California, San Diego, USAShort Talk: A Stress Activated p62-NRF2-MDM2 Axis DrivesPancreatic Tumorigenesis

Complex Microbiome Analyses (J8)*Julie A. Segre, NHGRI, National Institutes of Health, USARob Knight, University of California, San Diego, USAHuman Microbiome and Metabolome Dynamics

Eric J. Alm, Massachusetts Institute of Technology, USAFMT Complex AnalysesMichael A. Fischbach, University of California, San Francisco, USASmall Molecules from the Human MicrobiotaKatherine S. Pollard, University of California, San Francisco, USADecoding Cryptic Variation in the Human MicrobiomeKelly Wen Li Chen, Massachusetts Institute of Technology, USAShort Talk: Integrated Gut/Liver Microphysiological System ElucidatesCytokine/Chemokine Inter-Tissue Crosstalk under Endotoxin-InducedStress

Workshop 2: Inflammation and Immunity Crosstalk (J7)*Giorgio Trinchieri, NCI, National Institutes of Health, USA*Laurence Zitvogel, Institut Gustave Roussy, FranceGiuseppe Di Caro, University of California, San Diego, USAImmunoglobulin A Attenuates Colonic Tumorigenesis by ControllingMicrobial Translocation and Tumor-Elicited InflammationAnkit Malik, St Jude Children's Research Hospital, USAIL-33 Regulates the IgA-Microbiota Axis to Restrain IL-1alphaDependent Colitis and TumorigenesisAndrea Ponzetta, Humanitas Clinical and Research Center, ItalyNeutrophils are Protective in Cancerogenesis by Altering TumorMicroenvironment and Controlling Intestinal MicrobiotaSabine Waeber, Université de Lausanne, SwitzerlandMesenchymal Stem Cells from Human Squamous Cell LungCarcinoma Modulate Natural Killer (NK) Cell Phenotype and FunctionMartina Molgora, Humanitas Research Hospital, ItalyInterleukin-1 Receptor 8 (IL-1R8) Plays a Crucial Role in NaturalKiller Cell Differentiation and FunctionVenuprasad K. Poojary, Baylor Institute for Immunology Research,USAA Novel Role for Itch in Inhibition of IL-17-Mediated ColonInflammation and Tumorigenesis by ROR-gammat Ubiquitination Christoph Andreas Reichel, Walter Brendel Centre of ExperimentalMedicine, GermanyComplex Formation of uPA and PAI-1 Promotes Myeloid LeukocyteTrafficking

Panel: The Integrative Human Microbiome Project (iHMP) (J8)Gregory A. Buck†, Virginia Commonwealth University, USAPregnancy and Preterm Birth*Curtis Huttenhower, Harvard School of Public Health, USAInflammatory Bowel DiseaseGeorge M. Weinstock, The Jackson Laboratory, USAPrediabetesAnup Mahurkar, University of Maryland Baltimore, USA









Tumor Elicited Inflammation (J7)*Ming O. Li, Memorial Sloan-Kettering Cancer Center, USAYinling Hu, National Cancer Institute at Frederick, USAIKKalpha, Autoimmunity, and Chronic Fungal Infection in Esophagealand Skin Carcinogenesis Hua E. Yu, Beckman Research Institute, City of Hope, USAStat 3 in Cancer Inflammation and as a Target in CancerOwen J. Sansom, Beatson Institute of Cancer Research, UKTargeting Myeloid Cells in Epithelial CancersElena Tosti, Albert Einstein College of Medicine, USAShort Talk: MMR and Tgfb Signaling Cooperate in SuppressingInflammation-Associated Colorectal Tumorigenesis

Human Microbiome Studies (J8)*Ramnik Xavier, Massachusetts General Hospital and BroadInstitute, USAAndrew L. Goodman, Yale School of Medicine, USACooperation and competition in the human gut microbiomeJulie A. Segre, NHGRI, National Institutes of Health, USAHuman Skin Microbiome: Topographic Functional Mapping of HealthyVolunteers and Patient PopulationsGary D. Wu, University of Pennsylvania School of Medicine, USADiet, the Gut Microbiome, and Inflammatory Bowel DiseaseRenuka Nayak, University of California, San Francisco, USAShort Talk: Methotrexate Is an Antibacterial Drug Metabolized byHuman Gut Bacteria

Poster Session 2

WEDNESDAY, FEBRUARY 8Inflammation and Immunity Crosstalk I (J7)*Shannon J. Turley, Genentech, Inc., USAMichael Karin, University of California, San Diego, USAImmune Crosstalk in TumorsAlberto Mantovani, Humanitas University, ItalyInnate Immune Pathways and the Tumor MicroenvironmentMing O. Li, Memorial Sloan-Kettering Cancer Center, USAImmunity and Tolerance in CancerToby Lawrence, INSERM, FranceMechanisms of Tumour-Associated Macrophage (TAM) PolarisationSven Brandau, University Duisburg-Essen, GermanyShort Talk: Absence of Endogenous Toll-Like Receptor SensingUnleashes Protective Anti-Tumor Immunity and Tumor RegressionGeorge Plitas, Memorial Sloan Kettering Cancer Center, USAShort Talk: CD177 Identifies a Novel Subset of Regulatory T Cells(Treg) Infiltrating Human Breast Cancer

Genetic Diversity and Communication (J8)*Thaddeus S. Stappenbeck, Washington University School ofMedicine, USAKaren Guillemin, University of Oregon, USAModulation of Host Innate Immune Responses by IndividualMicrobiota MembersEran Segal, Weizmann Institute of Science, IsraelPersonalized Nutrition using Gut Microbiome and Clinical DataRobert E.W. Hancock, University of British Columbia, CanadaNetwork Biology Approaches to Understanding InflammationJames M. Musser, Methodist Hospital Research Institute, USAInterdisciplinary Studies of Select Major Human Bacterial PathogensMahesh S. Desai, Luxembourg Institute of Health, LuxembourgShort Talk: A Dietary Fiber-Deprived Gut Microbiota Degrades theColonic Mucus Barrier and Enhances Pathogen Susceptibility

Stromal Cells and the Tumor Microenvironment (J7)*Alberto Mantovani, Humanitas University, ItalyShannon J. Turley, Genentech, Inc., USALeukocyte Function and Positioning in Diverse Stromal NichesDaniel L. Worthley, SAHMRI, Adelaide, AustraliaIntestinal Mesenchyme in the Normal and Neoplastic ColonRaghu Kalluri, University of Texas MD Anderson Cancer Center, USAThe Functional Role of Inflammation and Fibrosis in Pancreatic Cancer

Microbiome and Disease (J8)*Timothy K. Lu, Massachusetts Institute of Technology, USAThaddeus S. Stappenbeck, Washington University School ofMedicine, USAMicrobial Metabolites that Modify Intestinal Wound RepairKathryn E. Holt, University of Melbourne, AustraliaKlebsiella Pneumoniae and the MicrobiomeAmi S. Bhatt, Stanford University, USAMetagenomics and the Microbiome in Stem Cell TransplantationLindsay R. Kalan, University of Pennsylvania, USAShort Talk: Multi-Kingdom Microbial Communities of ChronicNon-Healing Wounds and their Association with Clinical Outcomes

Poster Session 3

THURSDAY, FEBRUARY 9Inflammation and Immunity Crosstalk II (J7)*Jane L. Grogan, Genentech, Inc., USAWeiping Zou, University of Michigan, USAMetabolic Control of Effector T Cells and Regulatory T Cells in Tumor









Thomas Gajewski, University of Chicago, USAHost Factors Controlling Anti-Tumor Immunity: Unexpected Impact ofthe Commensal MicrobiotaE. John Wherry, University of Pennsylvania, USAMolecular Basis of T Cell Exhaustion: Insights for ImmunotherapyMartin Oft, ARMO BioSciences, USATalk Title to be AnnouncedBronislaw Pytowski, Eli Lilly, USAShort Talk: The Effect of VEGFR2 Inhibition on Tumor Blood Vesselsand Immune Landscape

Molecular Discovery of Novel Antimicrobials (J8)*Katherine S. Pollard, University of California, San Francisco, USAGautam Dantas, Washington University School of Medicine, USANetworks of Exchanging Antibiotic Resistance Between Commensal,Environmental, and Pathogenic BacteriaWilliam Michael Dunne, bioMérieux, Inc., USANext Generation Antimicrobial Susceptibility TestingAndreas Peschel, University of Tübingen, GermanyStaphylococcus Aureus in the Human Nose - A Facultative Pathogen'sInterference with MicrobiotaSilvio M. Vieira, Yale University, USAShort Talk: A Gut Commensal Breaches Both Gut Lymphatic andVascular Barriers to Drive Systemic AutoimmunityJonathan L. Linehan, NIAID, National Institutes of Health, USAShort Talk: Cutaneous Commensal Bacteria Drive an UnconventionalT Cell Response that Accelerates Wound Healing

Workshop 3: Prevention and Therapy (J7)*Carola H. Ries, Roche Innovation Center Munich, Germany*E. John Wherry, University of Pennsylvania, USAEduardo Bonavita, Cancer Research UK Manchester Institute,University of Manchester, UKCOX-2 Expression Positively Associates with Tumor-PromotingInflammatory Factors and Negatively with Anti-Tumor ImmunePathways in Human CancerDavid N. Brindley, University of Alberta, CanadaBlocking the Inflammatory Effects of Lysophosphatidate Signaling as aNew Strategy for Decreasing Tumor Growth, Metastasis and ImprovingChemotherapyFeng Zhu, NCI, National Institutes of Health, USAFungal Infection and Immune Dysfunction Contribute to EsophagealCarcinogenesis Kayla Knilans, NIAID, National Institutes of Health, USAType 2 Signaling Improves Survival and Reduces Tumor Growth in aMouse Model of Colitis-Associated Cancer

Jeff Kwak, University of Colorado Denver, USAComplement Activation Mediates Lung CancerProgression and Metastasis through Alterations inCD4 T LymphocytesMax Wellenstein, Netherlands Cancer Institute,NetherlandsLoss of p53 Drives Systemic NeutrophilicInflammation in Breast Cancer

Workshop 2: Metagenomic Analysis (J8)*Gautam Dantas, Washington University School ofMedicine, USAMichael G. Constantinides, NIAID, NationalInstitutes of Health, USAMucosal-Associated Invariant T Cells Respond toCutaneous MicrobiotaCollin Edington, Massachusetts Institute ofTechnology, USADevelopment of Bioreactor Devices for Microbiomeand Multi-Organ Interaction StudiesSho Kitamoto, University of MIchigan MedicalSchool, USAGut Inflammation-Driven Metabolic ReprogramingRegulates the Competitive Fitness of Pathogenic E.coliDavid T. Riglar, Harvard Medical School, USAGut Feelings: Engineering Synthetic Bacterial Circuitsto Functionally Probe the Mammalian Gut MicrobiomeNeil Surana, Harvard Medical School, USADiscovery of Disease-Modulating Microbiota UsingMicrobial Pedigree Analysis

Prevention and Therapy (J7)*Thomas Gajewski, University of Chicago, USACarola H. Ries, Roche Innovation Center Munich,GermanyCombining Macrophage Targeting with CancerImmunotherapiesJane L. Grogan, Genentech, Inc., USAThe Inhibitory Immunoreceptor TIGIT LimitsAnti-Tumor Immunity Jen Morton, Cancer Research UK Beatson Institute,ScotlandShort Talk: Myeloid Cells as a Therapeutic Target inPancreatic CancerKristen M. Larsen, University of South Carolina, USAShort Talk: The Role of Interleukin 33/ST2 Axis inLiver Metastasis of Colorectal Cancer

AlexandraZhernakova,UniversityMedicalCenterGroningen,NetherlandsShort Talk:Interaction ofGeneticsand FoodIntakeInfluencesGutMicrobiotaComposition

MeetingWrap-Up:Outcomesand FutureDirections(Organizers)(J7)MeetingWrap-Up:Outcomesand FutureDirections(Organizers)(J8)

FRIDAY,FEBRUARY10Departure









Systems Microbiology (J8)*Karen Guillemin, University of Oregon, USATimothy K. Lu, Massachusetts Institute ofTechnology, USAEngineering the MicrobiomeJames Amos-Landgraf, University of Missouri, USASuppression of Tumor Growth using BiofilmProducing Sulfate-Reducing Bacteria in a Rat Modelof Colon CancerSean F. Brady, Rockefeller University, USAMicrobial Biosynthetic Diversity









Documents

Inflammation-Driven Cancer: Mechanisms to Therapymembs.org/membs/uploads/news_images/cancer_document.pdf · immunity and inflammation are key determinants of tumor development and